Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
BUSINESS
J&J Files Tremfya SC Induction Regimen for UC in Japan
Janssen Pharmaceutical (J&J) said on March 6 that it has filed an application seeking Japanese regulatory approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat moderately to severely active ulcerative colitis (UC). In Japan, the anti-IL-23 antibody is…
To read the full story
Related Article
- Tremfya Filed for Crohn’s Disease in Japan: J&J
August 13, 2024
- Janssen Files Tremfya for Ulcerative Colitis in Japan
April 26, 2024
BUSINESS
- J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
- Biogen Launches Higher-Dose Spinraza in Japan
November 12, 2025
- Meiji Pharma to Set Up Singapore Subsidiary to Drive ASEAN Biz
November 12, 2025
- Alfresa Deepens Tie-Up with China Wholesaler to Support Japan-to-China Licensing
November 12, 2025
- Japan’s Generic, Biosimilar Market Seen Topping 2 Trillion Yen in 2033: Fuji Keizai
November 12, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…